Trading BioPhama stocks before a catalyst event, if done correctly can be a very profitable proposition, but if traded in a wrong manner, can cause losses. I remarked in an article from March of this year that Horizon Pharma (NASDAQ:…
Month: November 2012
November 10 Biotech Update
This past week was a bit rough on the overall markets as on Tuesday, the markets seemed to bet on a Romney win, only to sell off the next day on news of an Obama win. The good news for…
5 Biotech Stocks Poised For Nice Upside Gains
The following 5 biotech companies have strong catalysts and/or strong chart signals that indicate a trade to the long side could be in order. With the current choppy markets, opportunities for long trades are few and far between. I will…
Amicus Therapeutics Should See a Big Upside Move On Positive Phase 3 Data
One company that has really received a ton of attention lately has been Sarepta Therapeutics (SRPT). Only a few weeks ago, the stock was trading in the $3 to $4 range. On 10/3/12, the company announced that it received positive…
Quantitative Easing: Fractioning The Dollar, Undervaluing The Markets
On a regular basis, I hear guests on CNBC constantly saying the market is overbought. After awhile, I wonder if these individuals learned about modern finance from a Cracker-Jack box. These same people were screaming at the world in 2008…